annual cash & cash equivalents:
$51.87M+$8.95M(+20.84%)Summary
- As of today (September 9, 2025), AKBA annual cash & cash equivalents is $51.87 million, with the most recent change of +$8.95 million (+20.84%) on December 31, 2024.
- During the last 3 years, AKBA annual cash & cash equivalents has fallen by -$97.93 million (-65.37%).
- AKBA annual cash & cash equivalents is now -83.87% below its all-time high of $321.64 million, reached on December 31, 2018.
Performance
AKBA Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$137.31M+$23.93M(+21.11%)Summary
- As of today (September 9, 2025), AKBA quarterly cash & cash equivalents is $137.31 million, with the most recent change of +$23.93 million (+21.11%) on June 1, 2025.
- Over the past year, AKBA quarterly cash & cash equivalents has increased by +$97.81 million (+247.62%).
- AKBA quarterly cash & cash equivalents is now -65.85% below its all-time high of $402.12 million, reached on June 30, 2018.
Performance
AKBA quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
AKBA Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +20.8% | +247.6% |
| 3 y3 years | -65.4% | -4.6% |
| 5 y5 years | -64.9% | -53.6% |
AKBA Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -65.4% | +20.8% | -5.2% | +303.6% |
| 5 y | 5-year | -80.7% | +20.8% | -53.6% | +303.6% |
| alltime | all time | -83.9% | +3060.9% | -65.8% | +8267.3% |
AKBA Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $137.31M(+21.1%) |
| Mar 2025 | - | $113.37M(+118.6%) |
| Dec 2024 | $51.87M(+20.8%) | $51.87M(+52.5%) |
| Sep 2024 | - | $34.02M(-13.9%) |
| Jun 2024 | - | $39.50M(-5.9%) |
| Mar 2024 | - | $41.96M(-2.2%) |
| Dec 2023 | $42.92M(-52.6%) | $42.92M(-7.7%) |
| Sep 2023 | - | $46.53M(-13.1%) |
| Jun 2023 | - | $53.57M(-5.9%) |
| Mar 2023 | - | $56.95M(-37.0%) |
| Dec 2022 | $90.47M(-39.6%) | $90.47M(-37.5%) |
| Sep 2022 | - | $144.76M(+0.6%) |
| Jun 2022 | - | $143.89M(-17.6%) |
| Mar 2022 | - | $174.56M(+16.5%) |
| Dec 2021 | $149.80M(-44.3%) | $149.80M(-27.7%) |
| Sep 2021 | - | $207.20M(-16.1%) |
| Jun 2021 | - | $246.99M(-9.4%) |
| Mar 2021 | - | $272.76M(+1.4%) |
| Dec 2020 | $269.08M(+81.9%) | $269.08M(-0.2%) |
| Sep 2020 | - | $269.65M(-8.8%) |
| Jun 2020 | - | $295.74M(+155.5%) |
| Mar 2020 | - | $115.77M(-21.8%) |
| Dec 2019 | $147.96M | $147.96M(+1.4%) |
| Sep 2019 | - | $145.88M(+6.4%) |
| Jun 2019 | - | $137.13M(-18.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2019 | - | $168.04M(-47.8%) |
| Dec 2018 | $321.64M(+1.2%) | $321.64M(-17.6%) |
| Sep 2018 | - | $390.14M(-3.0%) |
| Jun 2018 | - | $402.12M(+2.3%) |
| Mar 2018 | - | $393.03M(+23.7%) |
| Dec 2017 | $317.79M(+22.1%) | $317.79M(-3.6%) |
| Sep 2017 | - | $329.70M(+2.6%) |
| Jun 2017 | - | $321.21M(+27.6%) |
| Mar 2017 | - | $251.81M(-3.3%) |
| Dec 2016 | $260.34M(+88.0%) | $260.34M(+61.4%) |
| Sep 2016 | - | $161.32M(-14.5%) |
| Jun 2016 | - | $188.65M(-13.1%) |
| Mar 2016 | - | $217.03M(+56.7%) |
| Dec 2015 | $138.45M(+27.1%) | $138.45M(-12.1%) |
| Sep 2015 | - | $157.47M(+3.1%) |
| Jun 2015 | - | $152.79M(+52.3%) |
| Mar 2015 | - | $100.33M(-7.9%) |
| Dec 2014 | $108.92M(+234.6%) | $108.92M(-8.0%) |
| Sep 2014 | - | $118.34M(-4.8%) |
| Jun 2014 | - | $124.25M(-6.0%) |
| Mar 2014 | - | $132.15M(+305.9%) |
| Dec 2013 | $32.56M(+1883.9%) | $32.56M(+1883.9%) |
| Dec 2012 | $1.64M(-74.3%) | - |
| Dec 2012 | - | $1.64M |
| Dec 2011 | $6.38M | - |
FAQ
- What is Akebia Therapeutics, Inc. annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Akebia Therapeutics, Inc.?
- What is Akebia Therapeutics, Inc. annual cash & cash equivalents year-on-year change?
- What is Akebia Therapeutics, Inc. quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Akebia Therapeutics, Inc.?
- What is Akebia Therapeutics, Inc. quarterly cash & cash equivalents year-on-year change?
What is Akebia Therapeutics, Inc. annual cash & cash equivalents?
The current annual cash & cash equivalents of AKBA is $51.87M
What is the all time high annual cash & cash equivalents for Akebia Therapeutics, Inc.?
Akebia Therapeutics, Inc. all-time high annual cash & cash equivalents is $321.64M
What is Akebia Therapeutics, Inc. annual cash & cash equivalents year-on-year change?
Over the past year, AKBA annual cash & cash equivalents has changed by +$8.95M (+20.84%)
What is Akebia Therapeutics, Inc. quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of AKBA is $137.31M
What is the all time high quarterly cash & cash equivalents for Akebia Therapeutics, Inc.?
Akebia Therapeutics, Inc. all-time high quarterly cash & cash equivalents is $402.12M
What is Akebia Therapeutics, Inc. quarterly cash & cash equivalents year-on-year change?
Over the past year, AKBA quarterly cash & cash equivalents has changed by +$97.81M (+247.62%)